BPC-157 and Cancer Risk: The Angiogenesis Question
BPC-157 Safety
0 human cancer studies
No clinical trial has evaluated whether BPC-157 promotes or inhibits tumor growth in humans. The cancer risk question remains entirely unresolved.
McGuire et al., Current Reviews in Musculoskeletal Medicine, 2025
McGuire et al., Current Reviews in Musculoskeletal Medicine, 2025
View as imageBPC-157 grows blood vessels. That is one of its most well-documented effects in animal models, demonstrated across muscle, tendon, bone, and gastrointestinal tissue.[1] The mechanism runs through VEGFR2, the same receptor that pharmaceutical companies have spent billions targeting with anti-cancer drugs like bevacizumab (Avastin). This creates a straightforward biological question: if a peptide activates the pathway that oncologists try to shut down, what happens when cancer cells are present? The answer, as of 2026, is that nobody has tested this in humans. Not once. This article reviews every piece of relevant evidence that exists, from the molecular mechanism through the animal data to the one in vitro study on cancer cells, and maps exactly where the knowledge stops. For broader context on BPC-157's evidence base, the cluster pillar covers who is producing the data and why that matters.
Key Takeaways
- BPC-157 upregulates VEGFR2 expression and activates the VEGFR2-Akt-eNOS signaling pathway in human endothelial cells, increasing blood vessel formation in chick and rat models (Hsieh et al., 2017, Journal of Molecular Medicine).[1]
- VEGFR2 is the primary receptor targeted by anti-angiogenic cancer drugs; roughly half of human cancers depend on VEGF/VEGFR2 signaling for tumor vascularization.[7]
- One 2004 in vitro study reported BPC-157 reduced melanoma cell S-phase fraction by up to 55% and decreased ERK phosphorylation via the MAPK pathway. This study has never been replicated.[5]
- In cancer cachexia mice (C26 colon adenocarcinoma), BPC-157 counteracted muscle wasting and prolonged survival but did not reduce tumor volume (Kang et al., 2018).[3]
- No clinical trial has evaluated BPC-157's effect on tumor growth, tumor promotion, or metastasis in any cancer type (McGuire et al., 2025).[7]
- Preclinical toxicology in mice, rats, rabbits, and dogs found no test-related adverse effects at any dose tested, but these studies were not designed to detect tumor-promoting effects (Xu et al., 2020).[6]
How BPC-157 promotes angiogenesis
The pro-angiogenic mechanism of BPC-157 was characterized by Hsieh et al. (2017) at Chang Gung University in Taiwan, one of the few research groups outside of Zagreb to publish original BPC-157 data. Using human vascular endothelial cells, they demonstrated that BPC-157 increases both mRNA and protein expression of VEGFR2 (vascular endothelial growth factor receptor 2) without increasing VEGF-A itself. BPC-157 also promoted VEGFR2 internalization, a process that activates downstream signaling. The activated pathway follows the sequence VEGFR2 to Akt to eNOS, increasing nitric oxide production in endothelial cells.[1]
In the chick chorioallantoic membrane (CAM) assay, BPC-157 increased vessel density. In rats with surgically induced hind limb ischemia, BPC-157 accelerated blood flow recovery and increased vessel numbers in the ischemic muscle. Histological analysis confirmed increased VEGFR2 expression in the treated vessels.[1]
Earlier work by Brcic et al. (2009) at the University of Zagreb had shown that BPC-157 upregulates VEGF expression during muscle and tendon healing in rats. Immunohistochemical analysis using VEGF, CD34, and FVIII antibodies showed "adequately modulated angiogenesis" in BPC-157-treated animals, with the angiogenic response correlated to the healing process rather than occurring as an independent, unregulated effect.[2]
Seiwerth et al. (2018) reviewed BPC-157's angiogenic activity alongside standard growth factors (VEGF, FGF, EGF, HGF) across multiple tissue types. They proposed that BPC-157 interacts with the FAK-paxillin pathway, promoting cell survival and migration through integrin signaling rather than acting as a simple VEGF mimic. The review positions BPC-157 as a modulator of angiogenesis rather than a unidirectional promoter, arguing that the peptide's effects on vessel formation are context-dependent and coordinated with tissue repair.[5]
A 2020 study by the same Taiwan group (Hsieh et al.) extended the mechanistic picture, showing BPC-157 activates the Src-Caveolin-1-eNOS pathway in isolated aorta preparations, producing concentration-dependent and nitric oxide-dependent vasomotor effects. Src kinase inhibition abolished the signaling cascade, confirming the upstream role of Src in BPC-157's vascular effects.[11]
Why VEGFR2 activation raises cancer concerns
VEGFR2 is the dominant receptor mediating tumor angiogenesis. When tumors grow beyond approximately 1-2 millimeters in diameter, they require their own blood supply. They acquire it by secreting VEGF, which binds VEGFR2 on nearby endothelial cells, triggering new vessel formation that feeds the tumor with oxygen and nutrients. This process, first described by Judah Folkman in the 1970s, became the basis for an entire class of anti-cancer drugs.
Bevacizumab (Avastin), approved in 2004, works by binding VEGF-A and preventing it from activating VEGFR2. Ramucirumab (Cyramza) directly blocks the VEGFR2 receptor itself. Multiple tyrosine kinase inhibitors (sunitinib, sorafenib, pazopanib) target VEGFR2 among other kinases. These drugs are used across gastric, colorectal, lung, kidney, liver, and ovarian cancers precisely because VEGF/VEGFR2 signaling is active in roughly half of all human malignancies.[7]
The concern is mechanistically direct: BPC-157 upregulates the receptor that anti-cancer drugs are designed to block. If someone harbors a subclinical malignancy, a pre-cancerous lesion, or dormant micrometastases, a compound that increases VEGFR2 expression and activation could theoretically accelerate tumor vascularization, progression, and metastatic spread.
McGuire et al. (2025) stated this clearly in their narrative review: "No published in vivo data demonstrate that BPC 157 inhibits tumor progression, reduces tumor volume, or suppresses metastasis." They noted that "the proangiogenic properties of BPC-157 raise notable concerns regarding use in individuals who may harbor subclinical or undiagnosed malignancies."[7]
Jozwiak et al. (2025) reached a similar conclusion in their literature and patent review, acknowledging that speculation about BPC-157's angiogenic effects and potential tumor-promoting properties is a legitimate scientific concern that has not been experimentally resolved.[9]
The one cancer cell study: melanoma in vitro (2004)
The only published experiment directly testing BPC-157 against cancer cells is Radeljak, Seiwerth, and Sikiric (2004), presented as a conference abstract at the International Pigment Cell Conference and published in Melanoma Research. The study used a human melanoma cell line (FemX) and measured cell cycle progression and MAPK signaling in response to BPC-157 treatment.
At a concentration of 2 pg/mL, BPC-157 decreased the percentage of cells in S-phase (the DNA replication phase) by 20% compared to controls. At higher concentrations (2 ng and 10 ng), BPC-157 lowered the total S-phase fraction by up to 55%. Western blot analysis showed decreased phosphorylation of ERK (via the MEK/MAPK pathway) in cells treated with 10 ng BPC-157. When VEGF and BPC-157 were administered together, ERK phosphorylation was still reduced compared to cells treated with VEGF alone.[5]
This result is frequently cited as evidence that BPC-157 has anti-cancer properties, but several qualifications are critical:
It was a conference abstract, not a peer-reviewed full paper. The full methodology, statistical analysis, and complete dataset have never been published.
It has never been replicated. In over twenty years since publication, no independent laboratory has reproduced these findings, and even the original authors have not published a full-length follow-up.
One cell line tells you almost nothing about cancer biology in vivo. Thousands of compounds inhibit cancer cell growth in a dish. The overwhelming majority fail in animal models and human trials. In vitro melanoma inhibition does not predict what would happen in a living organism with an intact immune system, tumor microenvironment, and complex vascular network.
The authors are from the Sikiric group in Zagreb. The same group that produces the vast majority of BPC-157 research. Independent replication is the standard for establishing any pharmacological effect, and this study has not met that standard.
Cancer cachexia: the closest thing to a tumor model
The most relevant animal study is Kang et al. (2018), who tested BPC-157 in mice bearing C26 colon adenocarcinoma tumors, a standard model for cancer cachexia. Cancer cachexia is the wasting syndrome that occurs in over 50% of terminal cancer patients, characterized by progressive skeletal muscle loss and weight loss that cannot be reversed by nutritional support.
BPC-157 counteracted the cachexia: it reversed muscle wasting, normalized body weight loss, and prolonged survival. The peptide reduced pro-inflammatory and pro-cachectic cytokines (IL-6, TNF-alpha) and corrected deranged muscle proliferation pathways through FoxO3a, p-AKT, p-mTOR, and p-GSK-3beta signaling.[3]
What this study did not show: tumor volume reduction. The C26 tumors continued to grow. BPC-157 addressed the systemic consequences of cancer (muscle wasting, inflammation, weight loss) without demonstrating anti-tumor activity. Although tumor volume was numerically lower in the BPC-157 group, the difference did not reach statistical significance.
This is the critical data point that neither supporters nor critics of BPC-157 should ignore. In the only animal model where BPC-157 was administered alongside an actual growing tumor, the tumor kept growing. The peptide did not shrink it. It also did not cause the tumor to grow faster, at least not to a statistically detectable degree in this single study. But one experiment in one tumor model with a non-significant result does not resolve the question in either direction.
What the preclinical safety data covers (and what it misses)
Xu et al. (2020) published the most comprehensive preclinical safety evaluation of BPC-157 to date, testing the peptide in mice, rats, rabbits, and dogs. Single-dose toxicity studies showed no test-related adverse effects. Repeated-dose studies in dogs showed the compound was well tolerated, with no abnormal changes between BPC-157 and control groups. Genotoxicity testing (Ames test, chromosome aberration assay, micronucleus test) was negative across all assays.[6]
These studies were designed to detect acute and subacute toxicity, not carcinogenicity. A standard carcinogenicity study requires treating rodents for two years and then examining tissues for tumor incidence. No such study has been published for BPC-157. The negative genotoxicity results are reassuring (BPC-157 does not directly damage DNA), but they do not address whether the peptide could promote tumor growth in tissue where cancer is already initiating through its pro-angiogenic effects.
Lee et al. (2025) published the first human intravenous safety study, administering up to 20 mg of BPC-157 to healthy adults. The peptide was well tolerated with no adverse effects. This study was not designed to detect tumor promotion and followed subjects for a short duration only.[10]
The Sikiric group's response to cancer concerns
Sikiric et al. (2025) published a commentary defending BPC-157's safety profile in response to the concerns raised by Jozwiak et al. They argued that BPC-157 should be understood as a modulator of angiogenesis and nitric oxide signaling, not a simple angiogenesis promoter. Their position is that BPC-157 promotes "controlled and modulated" angiogenesis for tissue repair while maintaining, promoting, or recovering the essential protective functions of nitric oxide signaling.[8]
The argument rests on the concept that healing angiogenesis and tumor angiogenesis are biologically distinct processes. In wound healing, new vessels form in an organized pattern, mature properly, and support tissue repair. In tumor angiogenesis, vessels are disorganized, leaky, tortuous, and poorly functional. If BPC-157 promotes only the former and not the latter, the cancer concern may be less acute than the shared VEGFR2 pathway suggests.
This is a reasonable hypothesis. It is also unproven. No experiment has directly compared BPC-157's effect on organized tissue repair angiogenesis versus chaotic tumor angiogenesis in the same model. The concept of "selective" or "modulatory" angiogenesis is invoked but not experimentally demonstrated in a cancer context. The 80%+ of BPC-157 publications from a single research group makes independent validation essential before this hypothesis can be considered established.[4]
Where the evidence stops
The current state of evidence can be mapped precisely:
What has been demonstrated: BPC-157 upregulates VEGFR2 and promotes angiogenesis in healthy tissue models. BPC-157 does not directly damage DNA. BPC-157 counteracts cancer cachexia in one mouse model without statistically significant effects on tumor volume. One in vitro study suggested BPC-157 inhibits melanoma cell growth through MAPK pathway modulation.
What has never been tested: BPC-157 in any animal model of tumor initiation, progression, or metastasis. BPC-157 in animals with pre-malignant lesions. BPC-157 in any cancer patient or cancer survivor. Long-term carcinogenicity studies. The effect of BPC-157 on dormant micrometastases. Whether BPC-157's angiogenic effects differ between healing tissue and tumor tissue.
What this means: The cancer risk question for BPC-157 is genuinely unresolved. It is not theoretical fearmongering, because the VEGFR2 mechanism is real and well-characterized. It is not established danger, because no study has shown BPC-157 actually promotes tumor growth. It sits in the space between mechanism-based concern and absence of evidence, which is fundamentally different from evidence of absence.
The gap in human clinical data compounds this uncertainty. The animal safety studies that do exist were not designed to answer the cancer question. And the concentration of evidence in a single lab means that even the most reassuring interpretations of the data lack the independent verification that would normally be required to consider a safety question settled.
The Bottom Line
BPC-157 activates VEGFR2, the same receptor that anti-cancer drugs target for inhibition. No study has shown BPC-157 causes cancer, but no study has been designed to test this. The one in vitro cancer cell experiment (melanoma, 2004) showed growth inhibition but has never been replicated. The one animal cancer model (C26 cachexia) showed the tumor kept growing. Until purpose-designed carcinogenicity studies and long-term human safety data exist, the cancer risk of BPC-157 remains an open question grounded in legitimate mechanistic biology.